SELLAS Life Sciences Group Inc buy Mori8
Start price
28.09.20
/
50%
€2.04
Target price
06.10.20
-
Performance (%)
12.38%
End price
06.10.20
€2.29
Summary
This prediction ended on 06.10.20 with a price of €2.29. The prediction had a final performance of 12.38%. Mori8 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
SELLAS Life Sciences Group Inc | 1.520% | 1.520% | -13.150% | -84.746% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% | 15.757% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% | 35.363% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% | 10.532% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% | 36.692% |
Comments by Mori8 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc
In the thread Trading SELLAS Life Sciences Group Inc
Buy beendet